Hemab Therapeutics Holdings

Coagulation disorder biotech Hemab Therapeutics Holdings sets terms for $200 million IPO, pricing this week   April 30, 2026 News Hemab Therapeutics prices upsized IPO at $18, the high end of the range Hemab Therapeutics Holdings, a Phase 3-ready biotech... Read more